from 0-20 mmol/l at baseline to 0-55 mmol/l at three months and then dropped to 0-4 mmol/l at seven months. The changes in markers of bone turnover are as shown in the table with a more than twofold rise in serum osteocalcin and the carboxyterminal propeptide of type 1 collagen (PICP) as markers of bone formation and a 1-5 fold rise in the level of the carboxyterminal cross linked telopeptide of type 1 collagen (ICTP) and urinary hydroxyproline/creatinine ratio (OHP/Cr) as markers of bone resorption. These reflect the general increase in bone turnover induced by growth hormone treatment.

<table>
<thead>
<tr>
<th>Months of treatment</th>
<th>Osteocalcin (ng/ml)</th>
<th>PICP (ng/ml)</th>
<th>ICTP (ng/ml)</th>
<th>OHP/Cr (umol/l mmol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>30</td>
<td>241</td>
<td>22-0</td>
<td>178</td>
</tr>
<tr>
<td>3</td>
<td>78</td>
<td>542</td>
<td>30-2</td>
<td>261</td>
</tr>
<tr>
<td>7</td>
<td>85</td>
<td>598</td>
<td>30-3</td>
<td>179</td>
</tr>
</tbody>
</table>

These initial results are encouraging and suggest a potential therapeutic role for growth hormone in this condition, although it remains to be seen whether the effect on the tubular reabsorption of phosphate can be maintained long term.

**Treatment of fragile X syndrome**

**EDITOR,—In Slaney et al's otherwise impressive and important paper on DNA testing for fragile X syndrome in schools for learning difficulties,† the authors state that 'treatment is not possible at the present time'. Although a cure is not possible at the present time there is good evidence for benefits of medical interventions (for example, the use of stimulants or folic acid for the frequently associated attentional deficits and hyperactivity), and specific educational approaches focusing on the profile of cognitive, social, and behavioural deficits frequently witnessed in young people with fragile X syndrome. In addition, behavioural psychotherapy techniques can be invaluable in tackling such maladaptive behaviours as hyperactivity, self injury, and obsessionality. Families are entitled to know that while the condition cannot be cured there is much that can be done to maximise affected individuals' potential and to minimise their handicaps.

**JEREMY TURK**
Department of Mental Health Services, St George’s Hospital Medical School, Jenner Wing, Cranmer Terrace, Tooting, London SW17 0RE


**Perianal infection with β haemolytic streptococcus**

**EDITOR,—I am writing in reference to the article by Wright and Butt on perianal infection with β haemolytic streptococcus. In the discussion of the article the authors note, 'the disorder has been mistaken for child abuse, leading to unnecessary social investigation and family distress'. It needs to be stressed that genital trauma and anal trauma can predispose to infection and that I have seen one case where a child sustained anal sexual trauma and subsequently developed perianal β haemolytic streptococcus infection. The β haemolytic streptococcus would find a traumatised anus an easier target than an untraumatised anus.

In my opinion, any child who presents with a perianal infection has to have sexual abuse considered as a possible diagnosis by the examining doctor.

**PETER M WINTERTON**
Child Sex Abuse Unit, Princess Margaret Hospital for Children, Perth, Western Australia 6001

Treatment of fragile X syndrome.

J Turk

Arch Dis Child 1995 72: 544
doi: 10.1136/adc.72.6.544

Updated information and services can be found at:
http://adc.bmj.com/content/72/6/544.1.citation

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/